Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners ... (646) 871-8481 This press release was published by a CLEAR® Verified individual. MENAFN27032025004107003653ID1109363759